APA (7th ed.) Citation

CE, T., H, M., A, A., X, L., Z, F., L, D., . . . RB, L. (2024). The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia. Blood cancer journal, 14(1), 192. https://doi.org/10.1038/s41408-024-01180-x

Chicago Style (17th ed.) Citation

CE, Toscan, et al. "The Third Generation AKR1C3-activated Prodrug, ACHM-025, Eradicates Disease in Preclinical Models of Aggressive T-cell Acute Lymphoblastic Leukemia." Blood Cancer Journal 14, no. 1 (2024): 192. https://doi.org/10.1038/s41408-024-01180-x.

MLA (9th ed.) Citation

CE, Toscan, et al. "The Third Generation AKR1C3-activated Prodrug, ACHM-025, Eradicates Disease in Preclinical Models of Aggressive T-cell Acute Lymphoblastic Leukemia." Blood Cancer Journal, vol. 14, no. 1, 2024, p. 192, https://doi.org/10.1038/s41408-024-01180-x.